238 related articles for article (PubMed ID: 32799090)
21. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.
Jóri B; Falk M; Hövel I; Weist P; Tiemann M; Heukamp LC; Griesinger F
Curr Oncol; 2022 Sep; 29(9):6628-6634. PubMed ID: 36135089
[TBL] [Abstract][Full Text] [Related]
22. Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
Yamazoe M; Ozasa H; Tsuji T; Funazo T; Yoshida H; Hashimoto K; Hosoya K; Ogimoto T; Ajimizu H; Yoshida H; Itotani R; Sakamori Y; Kuninaga K; Aoki W; Hirai T
Cancer Sci; 2023 Feb; 114(2):546-560. PubMed ID: 36285485
[TBL] [Abstract][Full Text] [Related]
23. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
[TBL] [Abstract][Full Text] [Related]
24. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Frost N; Christopoulos P; Kauffmann-Guerrero D; Stratmann J; Riedel R; Schaefer M; Alt J; Gütz S; Christoph DC; Laack E; Faehling M; Fischer R; Fenchel K; Haen S; Heukamp L; Schulz C; Griesinger F
Ther Adv Med Oncol; 2021; 13():1758835920980558. PubMed ID: 33613692
[TBL] [Abstract][Full Text] [Related]
25. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
26. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
27. A user's guide to lorlatinib.
Nagasaka M; Ge Y; Sukari A; Kukreja G; Ou SI
Crit Rev Oncol Hematol; 2020 Jul; 151():102969. PubMed ID: 32416346
[TBL] [Abstract][Full Text] [Related]
28. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapies for ROS1-rearranged non-small cell lung cancer.
Patil T; Simons E; Mushtaq R; Pacheco JM; Doebele RC; Bowles DW
Drugs Today (Barc); 2019 Oct; 55(10):641-652. PubMed ID: 31720561
[TBL] [Abstract][Full Text] [Related]
30. Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
Barata F; Aguiar C; Marques TR; Marques JB; Hespanhol V
Drug Saf; 2021 Aug; 44(8):825-834. PubMed ID: 34080177
[TBL] [Abstract][Full Text] [Related]
31. Lorlatinib induced proteinuria: A case report.
Lee CS; Wanchoo R; Seetharamu N
J Oncol Pharm Pract; 2021 Jun; 27(4):1037-1039. PubMed ID: 32996364
[TBL] [Abstract][Full Text] [Related]
32. In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non-small-cell Lung Cancer.
Schoenmaekers J; Dijkstra J; van der Wekken A; Paats M; Broen M; Brandts L; Dingemans AM; Hendriks L
Clin Lung Cancer; 2024 Mar; 25(2):168-174.e1. PubMed ID: 38151408
[TBL] [Abstract][Full Text] [Related]
33. LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC.
Alexander M; Wei J; Parakh S; John T; Kao S; Nagrial A; Bowyer S; Warburton L; Moore M; Hughes BGM; Clay TD; Pavlakis N; Solomon BJ; Itchins M
JTO Clin Res Rep; 2023 Apr; 4(4):100490. PubMed ID: 37077199
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
35. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract][Full Text] [Related]
36. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
37. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
[TBL] [Abstract][Full Text] [Related]
38. CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.
Ou SI; Zhu VW
Lung Cancer; 2019 Apr; 130():201-207. PubMed ID: 30885345
[TBL] [Abstract][Full Text] [Related]
39. Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Descourt R; Pérol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cadranel J; Cortot AB; Guisier F; Galland L; Do P; Schott R; Dansin É; Arrondeau J; Auliac JB; Geier M; Chouaïd C
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406523
[TBL] [Abstract][Full Text] [Related]
40. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT
Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]